Anupam Rasayan accelerates downstream integration through major equity acquisition in Bliss GVS Pharma

Specialty chemicals producer Anupam Rasayan India has structured a deal to purchase up to a 43.3% interest in Bliss GVS Pharma for INR 13,695.1 million, followed by a public tender offer for another 26%. The move bridges chemical supply with finished drug manufacturing.

According to official regulatory filings, Anupam Rasayan India has agreed to buy a 43.3% stake in Bliss GVS Pharma Ltd at INR 299 per share, totaling INR 13,695.1 million, alongside a mandatory open offer for an additional 26% from public equity holders. The financing combines a INR 3,000 million term loan and non-controlling, non-voting equity funding. Anupam Rasayan is an established Indian specialty chemicals producer, while Bliss GVS Pharma, founded in 1984, manufactures and exports diverse medical formulations with USFDA, EU-GMP, and WHO clearances.

This transaction transitions Anupam Rasayan into a fully integrated pharmaceutical platform, moving beyond ingredients into finished dosage forms. For the broader life sciences landscape, the merger highlights a growing trend of chemical suppliers absorbing downstream formulation assets to establish robust captive demand and capture higher margins. Operational alignment will likely optimize costs across European and US markets, leveraging Anupam Rasayan's existing Jayhawk assets to streamline market access.

Strategically, this corporate consolidation protects the combined enterprise from raw ingredient volatility while strengthening its competitive stance against non-integrated generic drug manufacturers. Financially, the acquisition is supported by a solid balance sheet, with Anupam Rasayan posting a 40% year-on-year increase in consolidated net profits to INR 2,221.9 million for the recent fiscal year.